lystn

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Anne Donohoe and Nick Opich are back for a new episode with special guest Janet Qi, Co-Founder and CEO of PurMinds NeuroPharma. As our first recorded episode in 2024, Janet joins us this week to discuss her interesting career path which led her to PurMinds, a neuroscience company working with psychedelic compounds to treat neurological disorders. In this episode, Janet shares more about the specific indications that PurMinds is targeting, like ALS, Parkinson’s and Traumatic Brain Injury; the company’s unique approach to developing these drugs; and highlights on what investors need to know for PurMind’s upcoming $10M Series A raise. If you are interested in learning more about Janet and PurMinds NeuroPharma, visit the links in our show notes. Also, be sure to follow PurMinds and Janet on LinkedIn and other top social media platforms. So, sit back and enjoy our conversation with Janet Qi of PurMinds NeuroPharma. Links, mentions, and socials: PurMinds NeuroPharma: purminds.com PurMinds NeuroPharma LinkedIn: linkedin.com/company/72375015    PurMinds X: twitter.com/PurMinds   PurMinds Instagram: instagram.com/purminds   Janet Qi LinkedIn: linkedin.com/in/janet-qi-b3ba9675      Show Credits: This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.  Special thanks to our Program Director Shea Gunther. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: X: @The_GreenRush Instagram: @thegreenrush_podcast LinkedIn: linkedin.com/company/thegreenrushpodcast Facebook: facebook.com/TheGreenRushPodcast  YouTube: youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true